| Literature DB >> 25547195 |
Stephen D J Makin1, F A B Cook, Martin S Dennis, Joanna M Wardlaw.
Abstract
BACKGROUND: The small vessel disease (SVD) that appears in the brain may be part of a multisystem disorder affecting other vascular beds such as the kidney and retina. Because renal failure is associated with both stroke and white matter hyperintensities we hypothesised that small vessel (lacunar) stroke would be more strongly associated with renal failure than cortical stroke. Therefore, we performed a systematic review and meta-analysis to establish first if lacunar stroke was associated with the renal function, and second, if cerebral small vessel disease seen on the MRI of patients without stroke was more common in patients with renal failure.Entities:
Mesh:
Year: 2014 PMID: 25547195 PMCID: PMC4335630 DOI: 10.1159/000369777
Source DB: PubMed Journal: Cerebrovasc Dis ISSN: 1015-9770 Impact factor: 2.762
Fig. 1Flow chart of search results.
Characteristics of studies included in the systematic review
| Study and population | Lacunar stroke definition | Imaging | Definition of renal impairment | Lacunar ischaemic stroke impaired/total | Non-lacunar ischaemic stroke impaired/total | |
|---|---|---|---|---|---|---|
| Studies which compared renal function between lacunar and non-lacunar stroke | ||||||
| Beamer [ | Setting: 2 hospitals | TOAST | not clear | Proteinuria >20 mg/l | 17/54 | 11/42 |
| Included: 96 patients up to 7 days post-stroke | ||||||
| Excluded: UTI and dialysis | ||||||
| Das [ | Setting: neurology department | TOAST | CT/MRI | proteinuria 20–200 ml/l | 13/42 | 6/18 |
| Included: 60 patients up to 4 weeks post-stroke | ||||||
| Excluded: known CKD | ||||||
| MacWalter [ | Setting: teaching hospital | OCSP | CT | eGFR <66 | 121/134 | 302/354 |
| Included: 488 patients 48 h post stroke | ||||||
| Excluded: dialysis | ||||||
| Rodríguez-Yáñez [ | Setting: teaching hospital | TOAST | CT | proteinuria <30 mg/l | 4/33 | 45/167 |
| Included: 200 patients within 24 h | ||||||
| Excluded: TPA/trial drug, brainstem stroke or known renal disease | ||||||
| Tsagalis [ | Setting: teaching hospital stroke data bank | TOAST | CT | >50% increase in creatinine from baseline | 72/378 | 403/1454 |
| Included: 2,155 patients <48 h post stroke with 2× creatinine measurements | ||||||
| Excluded: previous stroke | ||||||
| Naganuma [ | Setting: registry of thrombolysis patients in 10 stroke units | TOAST | CT/MRI | eGFR <60 | 5/28 | 181/550 |
| Included: 578 patients who were thrombolysed for ischaemic stroke | ||||||
| Excluded: patients disabled prior to stroke | ||||||
| Mostofsky [ | Setting: emergency department | TOAST | CT/MRI | eGFR <60 | 105/339 | 286/836 |
| Included: 1,175 consecutive patients | ||||||
| Excluded: IN-hospital stroke | ||||||
| Ueda [ | Setting: stroke unit | TOAST | MRI | eGFR <60 | 12/38 | 44/164 |
| Included: 202 consecutive ischaemic stroke patients | ||||||
| Excluded: acute kidney injury | ||||||
| Putaala [ | Setting: Helsinki young stroke registry | TOAST | not clear | eGFR <60 | 17/130 | 26/828 |
| Included: 958 first stroke patients age 15–19 | ||||||
| Excluded: incomplete data or creatinine measured 30 days post-stroke | ||||||
| Hoshino [ | Setting: Neurology Department | TOAST | CT | eGFR <60 | 29/92 | 88/235 |
| Included:475 stroke patients | ||||||
| Excluded: severe renal dysfunction, pre stroke disability | ||||||
| Kudo [ | Setting: single hospital | TOAST | CT/MRI | eGFR <60 and/or24/60 proteinuria | 168/264 | |
| Included: 525 stroke patients | ||||||
| Excluded: missing data | ||||||
| Tsukamoto [ | Setting: neurology department | TOAST | CT/MRI | eGFR <60 | 32/104 | 207/535 |
| Included: 639 consecutive stroke patients | ||||||
| Excluded: dialysis patients | ||||||
| Chinda [ | Setting: single hospital | TOAST | CT/MRI | eGFR <60 | 15/65 | 79/224 |
| Included: 451 consecutive stroke patients | ||||||
| Excluded: presented later than 7 days after stroke | ||||||
| Studies which compared renal function in stroke patients with WMH to those without WMH | ||||||
| Oksala [ | Setting: single hospital | NA | 1.0T MRI | eGFR <60 | 96/203 | 56/175 |
| Included: 378 consecutive ischaemic stroke patients aged 55–85 | ||||||
| Excluded: patients who were not Finnish or not living in Helsinki | ||||||
| Rost [ | Setting: Emergency Department | NA | 1.5T MRI | eGFR as a continuous relationship | low eGFR correlated with WMH volume, r = −0.003, p = 0.002 | |
| Included: 523 consecutive ischaemic stroke patients | ||||||
| Excluded: patients without a lesion on MRI | ||||||
| Studies of patients with MR imaging features of SVD, but no symptomatic stroke | ||||||
| Uzu [ | Setting: diabetic outpatient clinic | 1.5T MRI | 1+ SBI definition not given | micro albuminuria (30–299 ml/1) | 95/177 | 188/431 |
| Included: 608 type 2 diabetic | ||||||
| Excluded: IHD, cancer, steroid use, heavy proteinuria 300 ml/l+, renal impairment | ||||||
| Ikram [ | Setting: Rotterdam study: population based study of 7,983 participants over 50 | 1.5T MRI | automated measurement of WMH volume | eGFR | for each SD decrease in eGFR there was a significant increase in OR of WMH 0.16 (0.04–0.29) | |
| Included: subgroup of 484 participants aged 60–90 stratified by sex and age | ||||||
| Excluded: patients with known dementia, or who could not have MRI | ||||||
| de Bresser [ | Setting: patients aged 56–80 with diabetes recruited though their General Practitioners | 1.5T MRI | automated measurement of WMH volume | albuminuria >0.03 g/1 | baseline albuminuria was associated with a non-significant increase in WMH at 2 years | |
| Included: 122 patients with Type 2 diabetes | ||||||
| Excluded: patients with psychiatric and neurological disorders, heavy alcohol use and dementia | ||||||
| Seliger [ | Setting: Cardiovascular Health Study 5,888 individuals over 65 selected randomly from medicare lists | not clear | 1+ infarct-like lesion ≥3 mm in a patient without a history of stroke | eGFR <60 | 237/789 | 484/1,995 |
| Included: 2,784 participants selected for MRI | ||||||
| Excluded: previous stroke and TIA | ||||||
| Giele [ | Setting: second manifestations of ARTertial disease (SMART) study | 1.5T MRI | 1+ CSF filled lesion ≥3 mm | mild renal impairment: eGFR 80–50 Severe renal impairment eGFR <50 | age adjusted OR for presence of silent infarcts in: mild renal impairment 1.6 (0.7–3.5) | |
| Included: 308 patients with first presentation of atherosclerotic disease | ||||||
| Excluded: previous stroke or TIA | Severe renal impairment 7.3 (2.1–25.2) | |||||
| Wada [ | Setting: population study of all 61 and 72 year olds from two towns | 0.3 & 0.5T MRI | Fazekas score of either 2 or 3 (not specified whether deep or periventricular) | presence of micro albuminuria: cut off not clear | 95/177 | 188/431 |
| Included: 608 participants | ||||||
| Excluded: history of stroke, current UTI | ||||||
| eGFR <60 or urinary ACR <30 | 70/143 | 157/508 | ||||
| Cystatin C | OR of moderate or severe WMH, per SD increase in cystine C 1.48 (1.22–1.78) (unadjusted) | |||||
| Weiner [ | Setting: clients of a home care service for low income people over 60 | 1.5T MRI | a score of 2/10 or more on an unvalidated qualitative WMH rating scale | microalbuminuria (17 mg/g+ in men and 25 mg/g+ in women) | 88/214 | 29/105 |
| Included: 319 participants | ||||||
| Excluded: participants who were unable to consent, non-English speakers, had a visual or hearing disability, on dialysis or unable to provide a urine specimen | ||||||
| Otani [ | Setting: population study of one town | 0.5T MRI | at least 1 hyperintensity on T2 between 3 and 15 mm | eGFR <60 | 100/286 | 186/722 |
| Included: 1,008 participants aged over 55 | ||||||
| Excluded: previous stroke or TIA | ||||||
| Bouchi [ | Setting: patients with type 2 diabetes who had an MRI for any reason at a single hospital | 1.5T MRI | T2 hyperintensity ≥3 mm | eGFR <60 | 182/415 | 75/371 |
| Included: 786 participants | ||||||
| Excluded: patients with type 1 DM, pregnancy, infection, cancer, or eGFR under 15 | ||||||
| Chou [ | Setting: healthy volunteers from Taipai City | 1.5T MRI | T2 hyperintensity ≥3 mm | eGFR 30–60 | 10/62 | 37/1,250 |
| Included: 1,312 participants | ||||||
| Excluded: previous stroke, current fever, eGFR <30 | ||||||
| Anan [ | Setting: outpatient endocrinology clinic | 1.5T MRI | the presence of WMH with Fazekas score ≥2 – unclear if deep or periventricular | urinary albumin in the range of 30–299 mg/24 h | 27/34 | 20/56 |
| Included: 90 patients with type 2 diabetes | ||||||
| Excluded: patients with IHD, macro-albuminuria, high creatinine, or insulin use | ||||||
| Eguchi [ | Setting: asymptomatic patients having an annual health check | 0.5T MRI | at least 1 hyperintensity on T2 between 3 and 15 mm | correlation between serum creatinine and no of WMH | serum creatinine correlated with number of WMH, r = 0.2, p < 0.006 | |
| Included: 170 patients aged 42–89 with 3 or more vascular risk factors | ||||||
| Excluded: renal or liver failure, secondary or malignant hypertension | ||||||
| Khatri [ | Setting: randomly selected residents of Manhattan | 1.5T MRI | automated measurement of WMH volume | correlation between creatinine clearance and WMH volume | creatinine clearance of 15–60 ml/linked to log WMH volume (0.322; 95% CI, 0.095–0.550) | |
| Included: 615 participants over 40 who had a telephone and could consent | ||||||
| Excluded: those with a history of stroke or eGFR <15 | ||||||
| Takahashi [ | Setting: asymptomatic patients presenting for a ‘brain check’. | 1.5T MRI | score of ≥2 on Fazekas score – deep and periventricular lesions analysed separately | eGFR <60 | deep WMH 89/465 | deep WMH 156/1,571 |
| Included: 2,043 healthy volunteers. | ||||||
| Excluded: participants with a history of stroke, neurological, or heart diseases | ||||||
| periventricular WMH: 51/221 | periventricular WMH: 194/1,822 | |||||
| Takami [ | Setting: outpatient hypertension clinic | 1.5T MRI | deep WMH: cases if Fazekas score ≥2. Periventricular WMH cases if Fazekas score ≥1 | eGFR <60 | deep WMH 31/75 | deep WMH 16/110 |
| Included: 185 participants | ||||||
| Excluded: patients with AF | ||||||
| periventricular WMH 36/102 | periventricular WMH 10/83 | |||||
| Turner [ | Setting: members of sibling pairs where one was hypertensive | 1.5T MRI | automated measurement of WMH volume on FLAIR | correlation between serum creatinine and WMH volume | correlation between serum creatinine and WMH volume. Age adjusted correlation coefficient = 0.54 | |
| Included: 1,585 participants | ||||||
| Excluded: secondary hwypertension, known CKD and previous stroke | ||||||
| Ravera [ | Setting: patients from one centre who were enrolled in a large study on complications of microalbuminuria in untreated patients with mild-moderate hypertension | 1.5T MRI | a count of number of lacuanes: 3–15 mm lesion dark on T1, light on T2 | no of lacunes in 11 patients with microalbuminuria against the number of lacunas in 11 patients without microalbuminuria 82 of patients with microalbuminuria had incident lacunes vs. 27% of patients without | ||
| Included: 22 patients with microalbuminuria, 22 controls without | ||||||
| Excluded: patients with cancer, liver disease, IHD, diabetes, obesity, and Dementia | ||||||
1All studies excluded patients unable to have MRI
Calculated from mean and SD assuming a normal distribution. UTI = Urinary tract infection; TOAST = trial of org 10,172 in acute stroke treatment; CKD = chronic kidney disease; CT = computerised topography; MRI = magnetic resonance imaging; OCSP = oxfordshire community stroke project; eGFR = estimated glomular filtration rate; TPA = tissue plasminogen antigen; WMH = white matter hyperintensities; SD = standard deviation; IHD = ischaemic heart disease; TIA = transient ischaemic attack; CSF = cerebrospinal fluid; OR = odds ratio; ACR = albumin creatinine ratio.
Summary of characteristics of studies
| Characteristic | Number of studies | % of studies | % of subjects |
|---|---|---|---|
| Stroke patients | 14 | 45 | 37 |
| Non stroke | 17 | 55 | 63 |
| Studies of stroke patients | % of studies of stroke patients | % of stroke patients | |
| Recorded stroke sub-type | 13 | 87 | 88 |
| Inpatients and outpatients | 1 | 7 | 1.2 |
| Inpatients only | 12 | 80 | 96 |
| USA | 3 | 20 | 22 |
| Europe | 5 | 33 | 48 |
| Asia | 7 | 47 | 29 |
| Studies of subtyped stroke patients | % of studies that subtyped stroke | % of patients with subtyped stroke | |
| OCSP | 1 | 8 | 7 |
| TOAST | 12 | 92 | 93 |
| CT Imaging | 4 | 31 | 40 |
| MRI | 2 | 15 | 12 |
| CT and MRI | 4 | 31 | 17 |
| Measured proteinuria | 4 | 31 | 9 |
| Measured eGFR | 9 | 69 | 69 |
| Patients that developed acute kidney injury | 1 | 8 | 26 |
| Studies of imaging features of SVD patients | % of studies of imaging features of SVD | % of subjects in the studies of imaging features of SVD | |
| Healthy volunteers | 8 | 47 | 57 |
| Diabetic patients | 4 | 24 | 10 |
| Any vascular risk factor | 2 | 12 | 4 |
| Hypertensive patients | 1 | 6 | 0.2 |
| Hypertensive patients and their siblings | 1 | 6 | 11 |
| Excluded previous stroke | 10 | 59 | 84 |
| Excluded severe renal impairment | 9 | 53 | 35 |
| 1.5T | 14 | 82 | 86 |
| 0.5T | 3 | 18 | 14 |
| Fazekas or similar | 5 | 29 | 24 |
| Count of silent brain infarcts | 6 | 35 | 52 |
| Automated measure of the volume of WMH | 5 | 29 | 24 |
| Images analysed by a blinded observer | 9 | 53 | 46 |
| Measured eGFR | 8 | 47 | 70 |
| Measured proteinuria | 5 | 29 | 13 |
| Measured both | 3 | 18 | 14 |
| Measured serum creatinine | 1 | 6 | 2 |
| Multivariate analysis | 13 | 76 | 81 |
Fig. 2A forest plot demonstrating the results of the meta-analysis of studies of renal function in patients with lacunar and cortical stroke.
Fig. 3The Odds Ratio of renal impairment in patients with lacunar stroke compared to other stroke sub-type for different subgroups of studies.
Fig. 4Meta-analysis of the risk of renal impairment in non-stroke patients with SVD compared to those without SVD.
Fig. 5The Odds Ratio of renal impairment in non-stroke patients with small vessel disease compared to those without for different subgroups of studies.